Centre for Commercialization of Cancer Immunotherapy

Published purpose

This Project aims at establishing a current Good Manufacturing Practices (cGMP)-compliant platform to manufacture clinical grade lentiviral vectors (including production, purification and quality control) at the Centre of Excellence for Cellular Therapy (CETC) of Hôpital Maisonneuve-Rosemont. It builds on the capacity of the CETC, the only fully operational cGMP-compliant cell therapy facility in Canada, to generate viral vectors of clinical and commercial grade at the 50L scale. The Project involves: 1) generating the documentation during its purchase, 2) its qualification, 3) validation of the manufacture process, and 4) training and knowledge dissemination. At the end of the Project, a fully functional cGMP- compliant viral vector production manufacturing platform will be available in Canada to ensure accessibility of affordable cell and gene therapies for Canadians.